Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 22, Issue 14, Pages 1883-1887Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458516636959
Keywords
Multiple sclerosis; immunology; plasma microparticles; vascular endothelium; B cells; fingolimod; biological marker
Categories
Funding
- Dubbo MS Support Group
- MS Research Australia
- Novartis Australia
Ask authors/readers for more resources
Background: No molecular marker can monitor disease progression and treatment efficacy in multiple sclerosis (MS). Circulating microparticles represent a potential snapshot of disease activity at the blood brain barrier. Objectives and methods: To profile plasma microparticles by flow cytometry in MS and determine how fingolimod could impact endothelial microparticles production. Results: In non-treated MS patients compared to healthy and fingolimod-treated patients, endothelial microparticles were higher, while B-cell-microparticle numbers were lower. Fingolimod dramatically reduced tumour necrosis factor (TNF)-induced endothelial microparticle release in vitro. Conclusion: Fingolimod restored dysregulated endothelial and B-cell-microparticle numbers, which could serve as a biomarker in MS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available